Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Etanercept, adalimumab worth trying over infliximab for RA

    • 11 Accesses

    This is a preview of subscription content, log in to check access.

    REFERENCE

    1. 1.

      Wailoo AJ, Bansback N, Brennan A, Michaud K, Nixon RM, Wolfe F.Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis. Arthritis and Rheumatism 58: 939-946, No. 4, Apr 2008

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Etanercept, adalimumab worth trying over infliximab for RA. Pharmacoecon. Outcomes News 554, 6 (2008). https://doi.org/10.2165/00151234-200805540-00013

    Download citation

    Keywords

    • Rheumatoid Arthritis
    • Arthritis
    • Infliximab
    • Good Choice
    • Health Economic